CD8A and neoplasm: In preclinical models, MEK inhibition alone increased the tumour-infiltrating CD8+ T cells and induced MHC-I upregulation, the combination of MEK inhibition with an anti-PD-L1 resulted in synergistic and durable tumour regression [71].